---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126487"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:04:37.030767+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical reports Q3 revenue of $67,500 from first commercial sales of QUELIMMUNE; net loss narrows to $4.5M

## Summary
- First commercial revenue of $67,500 from direct QUELIMMUNE shipments to hospital customer; no revenue in Q3 2023.
- Net loss $4.5M ($1.10/share) vs $7.2M ($9.02/share) in Q3 2023; cash $2.1M as of Sep 30.
- Eliminated all $9M+ long-term debt during 2024; no long-term debt outstanding.
- FDA granted Breakthrough Device Designation for SCD in chronic dialysis (4th designation).
- NEUTRALIZE-AKI adult trial: 59 subjects enrolled, record October enrollment; 12 clinical sites.

## SEC filing metadata
- accession: 0000950170-24-126487
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000095017024126487/0000950170-24-126487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000095017024126487/icu-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126487
- JSON: https://secwatch.observer/filing/0000950170-24-126487.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.